title: Discriminating ability of spectral domain optical coherence tomography in different stages of glaucoma.
abstract: OBJECTIVE
  To determine the discriminating ability of retinal nerve fiber layer (RNFL) thickness measured with spectral-domain optical coherence tomography (SD-OCT) in different stages of glaucoma.
  
  
  METHODS
  Thirty normal, 150 glaucomatous eyes were included. Glaucomatous eyes were graded into early, moderate and severe stages according to one of the global indices called visual field index (VFI). Complete ophthalmic examination, white on white perimetry and SD-OCT were done for all patients. RNFL thickness of quadrants and average thickness were recorded. Area under receiver operating characteristic curves (AUCs) were used to assess the performance of OCT parameters.
  
  
  RESULTS
  AVERAGE, INFERIOR AND SUPERIOR RNFL THICKNESS WERE THE BEST PARAMETERS TO DISCRIMINATE NORMAL FROM EARLY GLAUCOMA (AUC: 0.91-86), early from moderate (AUC: 0.77-0.70) and moderate from severe (AUC: 0.85-83). Average RNFL loss was 18% in early glaucoma, 28% in moderate glaucoma and 41% in severe glaucoma. Early damage tends to be focal and in the lower quadrant. A significant correlation was detected between mean VFI and mean RNFL loss. Glaucoma was restaged according to average RNFL loss into early: ⩾97.5 μ, moderate: <97.5-72.5 μ and severe: <72.5 μ.
  
  
  CONCLUSIONS
  RNFL thickness measured with SD-OCT could discriminate the three stages of glaucoma. RNFL loss can be correlated to visual field loss. Future OCT-based staging of glaucoma, adjunctive to perimetry is possible.
authors: Mansoura Ophthalmic Center, Mansoura University, Egypt.
authors: Amal M
authors: AM
authors: Elbendary
authors: Randa
authors: R
authors: Mohamed Helal
keywords: Discrimination; Glaucoma; Optical coherence tomography; Perimetry; Stages
references: Ophthalmology. 2010 Sep;117(9):1684-91
references: 20663563
references: Open Ophthalmol J. 2009 Sep 17;3:59-64
references: 19834563
references: Surv Ophthalmol. 2007 Mar-Apr;52(2):156-79
references: 17355855
references: Arch Ophthalmol. 2006 Feb;124(2):169-76
references: 16476885
references: Am J Ophthalmol. 2007 Nov;144(5):724-32
references: 17868631
references: J Glaucoma. 2003 Feb;12(1):45-9
references: 12567111
references: Ophthalmology. 2011 Feb;118(2):241-8.e1
references: 20920824
references: Am J Ophthalmol. 2006 Jan;141(1):105-115
references: 16386983
references: Am J Ophthalmol. 2009 Oct;148(4):597-605
references: 19589493
references: Am J Ophthalmol. 2003 Apr;135(4):513-20
references: 12654369
references: Arch Ophthalmol. 2001 Jul;119(7):985-93
references: 11448320
references: J Glaucoma. 2009 Oct-Nov;18(8):608-17
references: 19826390
references: Ophthalmology. 2005 Jan;112(1):3-9
references: 15629813
references: Am J Ophthalmol. 2004 Feb;137(2):228-35
references: 14962410
references: Ophthalmology. 2010 Sep;117(9):1692-9, 1699.e1
references: 20493529
references: Am J Ophthalmol. 2008 Feb;145(2):343-53
references: 18078852
references: Arch Ophthalmol. 1982 Jan;100(1):135-46
references: 7055464
references: Invest Ophthalmol Vis Sci. 2001 Aug;42(9):1993-2003
references: 11481263